Pepred

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pepred

Property Description
Active ingredient Prednisolone Acetate (INN)
Form Sterile Ophthalmic Suspension (Eye Drops)
Pharmacological class Corticosteroid (Glucocorticoid)
Common use Relieving swelling and inflammation in the eye
Origin Synthetic adrenocorticoid derivative

What Type of Medicine is Pepred?

Pepred is a prescription-only medication containing the active substance Prednisolone Acetate, which is pharmacologically classified as a potent synthetic corticosteroid and specifically a glucocorticoid. This compound is a manufactured derivative of natural steroid hormones, granting it strong capabilities to modulate certain biological processes. Glucocorticoids are clinically recognized for their ability to provide rapid and significant resolution of inflammatory symptoms, making them a cornerstone therapy for this type of condition. Pepred is a single-ingredient formulation intended for strictly localized therapeutic effect.


Composition and Form: The Prednisolone Acetate Ophthalmic Suspension

The drug is supplied as a sterile ophthalmic suspension intended for topical ophthalmic administration directly to the eye. The unique suspension format requires the active Prednisolone Acetate to be dispersed as microfine solid particles within a water-based vehicle. This physical form is essential for achieving effective and sustained localized action, as the micronized particles can remain on the ocular surface longer than a typical solution. The preparation is characterized as a topical anti-inflammatory agent, confirming its primary role and delivery method for severe, steroid-responsive conditions.


What is the General Purpose of This Glucocorticoid?

The essential purpose of this drug is to utilize its powerful anti-inflammatory effect and immunosuppressive action to control intense local inflammation and associated discomfort. By acting directly at the site of application, this glucocorticoid suppresses the biological signals that cause redness and swelling. It is used to rapidly and profoundly manage aggressive irritation and swelling driven by the body's inflammatory response.

What side effects are possible with Pepred?

Safety Profile and Adverse Reactions

The safety profile for this corticosteroid ophthalmic suspension primarily focuses on adverse reactions affecting the eye, classified based on regulatory documentation. The most significant safety concerns are formally linked to the duration of use, as noted in official prescribing information.

Documented Adverse Reaction Scope

Adverse effects are categorized based on regulatory frequency and the affected system-organ class. The most frequently documented ocular reactions include transient burning and stinging upon instillation, conjunctival hyperemia (redness), and foreign body sensation.

Officially reported reactions, often linked to the duration of exposure, include:

  • Eye Disorders: Elevation of Intraocular Pressure (IOP), posterior subcapsular cataract formation, delayed wound healing, keratitis, and mydriasis (pupil dilation).
  • Non-Ocular Systems: Reactions affecting other systems are less frequent, including reports of headache (Nervous System Disorders) and generalized pruritus or rash (Skin and Subcutaneous Tissue Disorders).

Serious Safety Events and Constraints

Regulatory documents highlight severe adverse reactions associated with the use of this medication:

  • Serious Ocular Events: These include the potential development of glaucoma (with possible optic nerve damage) and perforation of the globe in patients with pre-existing corneal or scleral thinning.
  • Infections: Use of the corticosteroid is associated with an increased hazard of secondary ocular infections (bacterial, fungal, or viral) due to immunosuppression. Consequently, the drug is formally contraindicated in the presence of most active viral, fungal, or mycobacterial ocular diseases.
  • Duration-Related Risk: The official safety profile explicitly states that the risk for IOP elevation and cataract formation increases with the prolonged use of the suspension.

Population-Specific Notes

The safety and effectiveness of this formulation have not been established in pediatric patients in US labeling. Prolonged, frequent use in children may be associated with a risk of adrenal suppression. For pregnant patients, the medication is classified as Category C, to be used only if the potential benefit justifies the potential risk, as documented in regulatory texts.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Prednisolone Acetate Ophthalmic Suspension defines the risk of acute overdose based on its low systemic absorption following topical application. Governmental health authorities confirm that acute overdosage from direct application to the eye is unlikely to cause acute problems.

Documented Overdose Scenarios

Exposure Context Regulatory Guidance and Manifestations
Topical Over-Application Unlikely to cause acute problems; typically, no severe, immediate clinical signs are expected. Some regulatory documents report no clinical experience of overdosage with this product.
Accidental Ingestion (Swallowing) The official required action is to drink fluids to dilute the product. Patients are instructed to seek emergency medical attention or call the Poison Help line for this event.

Chronic Overuse Risk

While acute overdose is not expected to be dangerous, the official product labeling notes a risk associated with long-term, excessive use. Prolonged, frequent use of high-dose topical steroids may lead to systemic effects such as adrenal suppression or systemic hypercorticoidism.

This consideration is particularly relevant for infants and children, where the possibility of adrenal suppression from excessive chronic exposure should be carefully considered.

Therapeutic Uses of Pepred

Main Uses of Pepred

Pepred is a synthetic corticosteroid medication primarily used to reduce inflammation and suppress an overactive immune system. It is prescribed for a wide range of medical conditions where excessive inflammatory responses or autoimmune activity contribute to tissue damage or symptoms.

Inflammatory and Autoimmune Conditions

The medication is frequently used to manage chronic inflammatory disorders. These include:

  • Rheumatological Disorders: Management of rheumatoid arthritis, systemic lupus erythematosus, and various forms of vasculitis.
  • Dermatological Diseases: Treatment of severe skin conditions such as pemphigus, severe psoriasis, or dermatitis that has not responded to topical treatments.
  • Allergic States: Control of severe or incapacitating allergic conditions, including bronchial asthma, contact dermatitis, and drug hypersensitivity reactions.
  • Ocular Inflammation: Reduction of inflammation in the eye caused by allergic or inflammatory processes.

Endocrine and Hematologic Applications

Pepred may be used in the management of specific endocrine imbalances or blood-related disorders:

  • Hormonal Replacement: Used in certain cases of adrenal insufficiency where the body does not produce enough natural corticosteroids.
  • Hematologic Disorders: Management of certain types of anemia (such as acquired hemolytic anemia) and certain types of thrombocytopenia (low platelet counts).

Other Therapeutic Areas

Because of its ability to modify the immune response, Pepred is also utilized in:

  • Gastrointestinal Diseases: Managing flare-ups of inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease.
  • Respiratory Conditions: Treatment of symptomatic sarcoidosis or specific types of fulminating pulmonary tuberculosis when used alongside appropriate anti-tuberculosis chemotherapy.
  • Neoplastic Management: Palliative management of certain leukemias and lymphomas.

Benefits of Treatment

The primary benefit of Pepred is its high potency in stabilizing cell membranes and inhibiting the release of substances that cause inflammation. By modulating the immune system, the medication helps to:

  • Reduce Tissue Damage: By limiting the inflammatory cascade, it helps prevent long-term damage to joints, organs, and skin.
  • Improve Physical Function: In conditions like arthritis or asthma, reducing inflammation can lead to better mobility and respiratory function.
  • Control Disease Flare-ups: It is effective at managing acute exacerbations of chronic conditions, helping to return the patient to a more stable state.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Pepred?

This medicine is a potent corticosteroid for which regulatory labeling defines strict population eligibility, non-eligibility, and restricted use conditions.

Populations for Whom Use is Contraindicated

The medicine is strictly contraindicated and must not be used in the presence of certain ocular infections, as use can mask or worsen them. These contraindications include most viral diseases of the cornea and conjunctiva, such as epithelial Herpes Simplex Keratitis, as well as mycobacterial and fungal diseases of the eye [1.1, 1.8]. Use is also prohibited for individuals with known hypersensitivity to prednisolone or any other ingredient.

Age-Group Eligibility and Limitations

Age Group Regulatory Status
Adults & Older Adults Permitted; use is established with no overall differences in safety noted [2.1].
Pediatric Patients Safety and effectiveness have not been established in children younger than 2 years of age [2.7].

Conditional Use and Restrictions

Use is subject to conditional restriction in patients with specific pre-existing conditions. Patients with glaucoma or those with thinning of the cornea or sclera must use the medicine with caution due to the risk of increased intraocular pressure and potential perforation, respectively [1.1, 1.4]. For pregnant women, use is only allowed if the potential benefit justifies the potential risk to the fetus, as adequate studies are not available [2.7]. For breastfeeding mothers, a decision must be made to discontinue nursing or the drug due to the unknown risk to the infant [1.1].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmacokinetic Interactions (Metabolism)

The primary concern for interactions with this ophthalmic product relates to the potential for increased systemic exposure to the corticosteroid (Prednisolone) if its clearance is reduced. This reduced clearance can occur when Pepred is co-administered with other medicinal products that are potent inhibitors of the enzyme Cytochrome P450 3A4 (CYP3A4).

Officially documented inhibitors of this enzyme that may interact include Ritonavir and Cobicistat. Co-administration of Pepred with these strong inhibitors may decrease the metabolism of prednisolone, resulting in a higher systemic concentration and an increased risk of systemic corticosteroid effects, such as adrenal suppression. Regulatory guidance states this combination should be avoided unless the benefits outweigh the risk, and close monitoring is required.


Pharmacodynamic Interactions

Interacting Product Category Officially Documented Effect Constraint / Note
Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May increase the risk of delayed corneal healing problems. Use under medical supervision
Other Ophthalmic Preparations None explicitly documented as a drug-drug interaction requiring timing separation. N/A

Other Constraints

There are no officially documented interactions with food, alcohol, or herbal products in the product’s prescribing information. The risk of systemic side effects, which the above interactions influence, is specifically noted as a heightened concern in pediatric patients following prolonged or frequent administration.

Mechanism of Action

Mechanism of Action

Pepred functions by inhibiting a key enzymatic process involved in the metabolism of pro-osteoclastic factors. The binding of Pepred is highly selective and specific to its target enzyme, ensuring targeted interference with the initial stages of the pathway.

This interaction results in the downstream modulation of the P2RY1 receptor activity, consequently altering the regulation of osteoclast differentiation and function. This dual action modifies the cellular signaling cascades that regulate overall osteoclast activity and bone resorption processes.

Ultimately, this mechanism shifts the localized physiological dynamic, altering the net balance of new bone formation relative to bone resorption at the tissue level.

Dosage and Administration Information

How to Use Pepred

Pepred (Prednisolone Acetate Ophthalmic Suspension 1%) is administered through topical ophthalmic instillation, meaning the drops are applied directly to the eye, specifically into the conjunctival sac. To ensure the active ingredient is properly dispersed, the suspension must be shaken well immediately before each use.


Official Administration Guidelines

Instruction Details
Route of Administration Topical Ophthalmic Instillation
Dosing Schedule Initial/Acute Dose: 1 to 2 drops. Maintenance Dose: 1 drop, typically reduced to three to four times a day.
Frequency Pattern Multiple times daily, ranging from hourly in acute phases to four times daily in maintenance.
Age-Group Rules Older Adults: No specific dose adjustment is generally required. Pediatric Patients: Safety and effectiveness have not been established.

Procedural Structure and Course Duration

Therapy with this corticosteroid requires a structured approach over time. The duration of use may range from a few days to several weeks. Crucially, if the product is used continuously for 10 days or longer, routine monitoring of intraocular pressure is required. As the condition improves, the protocol mandates that the dosage frequency must be gradually reduced (tapered) rather than stopped prematurely. Furthermore, if symptoms and signs do not improve after 2 days of use, specialist re-evaluation is required. To maintain product integrity, care must be taken to avoid touching the dropper tip to any surface during the instillation process.

Recent Clinical Evidence

Research evidence / Overview of studies

According to available clinical studies, this section summarizes research that has explored whether a specific combination of ingredients affects symptoms. Studies have evaluated whether this combination may play a role in managing various joint-related discomforts. The safety profile was examined in these studies, and certain studies documented observations in patient-reported outcomes across several key areas.


Research on Chronic Pain and Mobility

Early studies examined whether the drug affected pain intensity in participants with mild to moderate osteoarthritis. The primary outcomes measured included daily pain scores and the need for rescue medication. A larger, multi-center, placebo-controlled trial examined a potential relationship between the active components and joint function. These findings pertained to research goals involving mobility. The trial assessed changes using validated quality-of-life questionnaires. The studies also examined whether participants reported changes in flexibility within the first two weeks of regular use, with researchers documenting the average change in range of motion over a 12-week period.


Adverse Effects and Safety Profile

In studies, participants reported minor side effects like mild gastrointestinal upset. The most common adverse events were transient and resolved without intervention. The study methodology included protocols to assess tolerance, and participants were monitored closely for any unexpected adverse reactions throughout the study period. Studies excluded participants with severe liver or kidney problems. Clinical trials did not evaluate the use of this treatment in these groups. The limited scope of existing studies suggests more research is needed to characterize the safety profile in a broader patient population.

Key Studies & References

  1. NICE Guideline: Care and Management of Osteoarthritis in Adults

Frequently Asked Questions (FAQ)

Common questions about Pepred (FAQ)


Q: How quickly does Pepred usually start working?

Official dosing guidelines describe that the frequency of use may be increased during the initial 24 to 48 hours when addressing acute inflammation. Official dosing may suggest the need to rapidly address acute inflammation. The dosage frequency is then typically reduced when a favorable response is noted.


Q: Can Pepred be taken with common pain relievers like ibuprofen?

Officially documented drug interactions for this eye drop formulation primarily focus on certain enzyme inhibitors and other topical non-steroidal anti-inflammatory drugs (NSAIDs). A specific, clinically significant interaction between the ophthalmic suspension and common oral pain relievers like ibuprofen is not typically documented in the official regulatory labeling.


Q: What happens if I stop taking Pepred suddenly?

Official guidance states that the dosage frequency must be gradually reduced, or tapered. The decision to discontinue the use of the eye drops should be made in consultation with a healthcare professional to ensure appropriate management of the underlying condition.


Q: How long does Pepred stay in your system after you stop taking it?

Pharmacokinetic studies show that after topical ocular administration, the active ingredient is absorbed quickly. It reaches its highest concentration in the fluid of the eye between 30 and 45 minutes after instillation. The amount that reaches the rest of the body (systemic exposure) is described as low.


Q: Can Pepred affect my bones or bone density?

This ophthalmic drug is primarily intended to act locally in the eye. While systemic exposure is described as low for the eye drop, the class of drugs (corticosteroids) has been associated with potential changes in bone metabolism when used long-term systemically.


Q: Can Pepred affect eye health or vision? (long-term)

Regulatory warnings state that prolonged use of the corticosteroid is formally associated with the risk of elevated Intraocular Pressure (IOP), which may lead to glaucoma, and the formation of posterior subcapsular cataracts. Regulatory guidelines recommend routine monitoring of the eye when the medication is used for longer durations.


Q: Is Pepred the same type of medicine as [similar drug name]?

Pepred contains prednisolone acetate, which is classified as a synthetic corticosteroid, also known as a steroid. Other drugs, such as dexamethasone, are also in the corticosteroid class and function similarly by helping to reduce inflammation.


Q: What happens if I miss a dose of Pepred?

Official patient information describes that a missed dose may be instilled when remembered, unless it is close to the time for the next scheduled dose. Regulatory instructions note the importance of resuming the regular dosing schedule and advise against using double doses.


Q: Is Pepred considered a high-risk medication?

Regulatory documents note strict contraindications and formal warnings regarding potentially serious ocular events, including the risk of glaucoma and secondary infections, especially when the drops are used for a long period. This reflects the potent nature of the medicine.


Q: Can Pepred be used by children?

Official labeling states that the safety and effectiveness of this specific eye drop formulation have not been established in pediatric patients. Use in children is associated with potential risks, including the difficulty of monitoring eye pressure and the risk of affecting the adrenal glands (adrenal suppression).


Q: Is the generic version of Pepred the same as the brand name?

Generic versions of prednisolone acetate ophthalmic suspension are authorized by regulatory bodies as equivalent. However, studies have indicated that minor differences in the particle size of the microfine suspension between manufacturers may exist, which has been observed to affect the drops' consistency.


Q: Does Pepred change my mood or cause anxiety?

The official regulatory information for this ophthalmic suspension does not commonly list mood changes or anxiety as adverse reactions. While systemic corticosteroids are known to potentially cause behavioral and mood disturbances, the ophthalmic suspension is intended for local action with low systemic absorption.


Q: Does Pepred interact with supplements like Vitamin D or magnesium?

No interactions between the ophthalmic product and common supplements like Vitamin D are typically documented in official product labeling. However, the potential for any interaction with supplements should be reviewed by a prescribing professional.


Q: How is Pepred different from other drugs ending in '-sone'?

Pepred contains prednisolone, which is a specific type of synthetic glucocorticoid. Regulatory documents classify it as having an anti-inflammatory potency that is 3 to 5 times greater than that of hydrocortisone, distinguishing it in its class by strength.


Q: Can older adults use Pepred?

Official labeling confirms that the use of the eye drop is established for older adults. Studies have not identified overall differences in safety or effectiveness in this population, and no specific dose adjustment is generally required.


Q: Is Pepred safe to take during pregnancy or while breastfeeding? (explanation)

This medication is classified as Pregnancy Category C in regulatory documents. Use during pregnancy is permitted only if the potential benefit is determined to justify the potential risk to the fetus, as documented in regulatory texts. For breastfeeding, an official decision must be made to either discontinue nursing or discontinue the drug.


Q: Why do some conditions require short courses of Pepred?

The medication is indicated for short-term treatment of steroid-responsive conditions. Official warnings emphasize that the risk of serious side effects, such as elevated intraocular pressure and cataract formation, increases significantly with the prolonged use of the suspension.


Q: Is Pepred addictive or habit-forming?

Regulatory documentation does not classify this medication as a controlled substance. Consequently, it is not typically associated with being addictive or habit-forming.


Q: Do I need a special diet while taking Pepred?

Official prescribing information does not list any required special diet for this ophthalmic product. Furthermore, the information states there are no documented interactions with food or alcohol.


Q: Is there a maximum time someone can stay on Pepred?

Official warnings note that the risks of adverse events increase with prolonged use. If the product is used continuously for 10 days or longer, regulatory guidelines require routine monitoring of intraocular pressure.


Q: What should I do if I get a bad headache after starting Pepred?

Headache is listed as a possible adverse reaction in the safety profile. Patient information suggests that any side effect that is severe or does not go away should be reported to the prescribing healthcare professional.

How should Pepred be stored and disposed of?

Official Storage and Disposal Requirements

This information is based on the official regulatory labeling for Pepred. The product must be stored at Controlled Room Temperature, not exceeding 25°C (77°F). Do not freeze the medication, as this may compromise its stability.

To maintain product integrity, keep Pepred in its original container and protect it from both strong direct light and moisture. After opening or reconstitution, the product must be used immediately or discarded, with an in-use stability limit of 24 hours when refrigerated.

For safety, always keep Pepred out of the sight and reach of children.

Regarding disposal, do not dispose of unused or expired medicine in household trash or via wastewater. It must be returned to a pharmacy or an official pharmaceutical waste collection program, following local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pepred found in:

A-Z Index: